Paziresh24
Paziresh24
Paziresh24 is a private Iranian healthtech platform focused on online appointment booking and digital access to doctors, hospitals, clinics, and online consultation services. In the Hormuz Group company graph, it matters because healthcare access increasingly depends on appointment systems, digital triage, physician discovery, patient data, online consultation, and platform trust. Its Tehran presence and earlier Yazd roots make it relevant to Iran's wider healthtech transition rather than only the capital market.
Products & Services
Paziresh24 operates a healthtech platform for online medical appointment booking, doctor discovery, hospital and clinic booking, online doctor consultation, patient reviews, medical-center profiles, physician pages, appointment management, health content, mobile application access, and digital workflow support for patients, doctors, clinics, hospitals, and healthcare centers.
Investment Relevance
Paziresh24 is relevant for investors assessing Iran's healthtech market, digital appointment infrastructure, online consultation demand, healthcare access gaps, physician-platform adoption, and patient acquisition in regulated medical services. It can support analysis of how digital platforms reduce friction in doctor discovery, clinic scheduling, hospital access, and telemedicine. Due diligence should verify the exact legal entity, ownership, medical and data-processing licenses, doctor and clinic coverage, active user metrics, monetization model, payment flows, patient-data governance, information-security controls, complaint handling, and exposure to healthcare regulation or platform restrictions.
Connected Intelligence
This profile is connected to Hormuz taxonomy layers across geography, industry, market exposure, and investment constraints.
Source & Verification Note
Based on public platform, official-website, app-store, healthtech, appointment-booking, online-consultation, healthcare-access, and market-related information. The exact legal entity should be verified before treating this profile as verified investment intelligence.